About the book
With the advances in biotechnology, identification of new therapeutic targets, and better understanding of human diseases, pharmaceutical companies and academic institutions have accelerated their efforts in drug discovery. The pipeline to obtain therapeutics often involves target identification and validation, lead discovery and optimization, pre-clinical animal studies, and eventually clinical trials to test the safety and effectiveness of the new drugs. In most cases, screening using genome-scale RNA interference (RNAi) technology or diverse compound libraries comprises the first step of the drug discovery initiatives. Conducting either genome-wide RNAi or small molecule screens has become possible with the advances in high-throughput screening (HTS) technologies, which are indispensable to carry out massive screens in a timely manner.
This book will analyze methods developed to meet the needs for handling large datasets generated from HTS campaigns. The growing number of statistical methods for HTS may further accelerate the discovery of drug candidates with higher confidence.